Compare Stocks Compare stocks with our powerful stock comparison tool. Analyze fundamentals, price performance, and key financial indicators to make informed investment decisions. Our tool lets you compare up to ten stocks side by side based on Performance Charts, Price & Volume, MarketRank™, Analyst Ratings, Sales & Book Value, Profitability & Earnings, Dividends, Debt, Ownership, Headlines, and more. Simply enter up to ten stock symbols (e.g., BAC, JPM, WFC, C, GS) to get started and uncover top investment opportunities. Stocks to Compare Sections All Sections Selected Performance Chart Price & Volume MarketRank Analyst Ratings Sales & Book Value Profitability & Earnings Dividends Debt Ownership Miscellaneous Headlines About Compare OTCMKTS:BLUSF NASDAQ:ESPR NASDAQ:INVA NASDAQ:YMAB On This Page Performance ChartPrice & VolumeMarketRank™Analyst RatingsSales & Book ValueProfitability & EarningsDividendsDebtOwnershipMiscellaneousHeadlinesAbout Comparison Ideas Stock Ideas Comparative Price Performance Over Time1 day7 days30 days90 days365 daysCompare Price & VolumeCompanyCurrent Price50-Day Moving Average52-Week RangeMarket CapBetaAvg. VolumeToday's VolumeBLUSFBELLUS Health$9.77$0.49▼$2.60$2.35B1.5539,610 shs3.45 million shsESPREsperion Therapeutics$2.52-6.7%$2.45$0.69▼$3.94$544.38M0.968.70 million shs9.04 million shsINVAInnoviva$17.39+4.3%$19.27$16.52▼$22.00$1.05B0.4730,490 shs828,751 shsYMABY-mAbs Therapeutics$8.61$8.57$3.55▼$16.11$391.24M0.54676,583 shsN/A(Almost) Everything You Need To Know About The EV MarketLooking to profit from the electric vehicle mega-trend? Enter your email address and we'll send you our list of which EV stocks show the most long-term potential.Get This Free ReportCompare Price PerformanceCompany1-Day Performance7-Day Performance30-Day Performance90-Day Performance1-Year PerformanceBLUSFBELLUS Health0.00%0.00%0.00%0.00%0.00%ESPREsperion Therapeutics-6.67%-1.95%-9.35%+103.23%+18.31%INVAInnoviva+4.32%+0.12%-11.05%-12.53%-12.53%YMABY-mAbs Therapeutics0.00%0.00%0.00%+99.31%-39.79%Compare Price & VolumeCompanyCurrent Price50-Day Moving Average52-Week RangeMarket CapBetaAvg. VolumeToday's VolumeBLUSFBELLUS Health$9.77$0.49▼$2.60$2.35B1.5539,610 shs3.45 million shsESPREsperion Therapeutics$2.52-6.7%$2.45$0.69▼$3.94$544.38M0.968.70 million shs9.04 million shsINVAInnoviva$17.39+4.3%$19.27$16.52▼$22.00$1.05B0.4730,490 shs828,751 shsYMABY-mAbs Therapeutics$8.61$8.57$3.55▼$16.11$391.24M0.54676,583 shsN/A(Almost) Everything You Need To Know About The EV MarketLooking to profit from the electric vehicle mega-trend? Enter your email address and we'll send you our list of which EV stocks show the most long-term potential.Get This Free ReportCompare Price PerformanceCompany1-Day Performance7-Day Performance30-Day Performance90-Day Performance1-Year PerformanceBLUSFBELLUS Health0.00%0.00%0.00%0.00%0.00%ESPREsperion Therapeutics-6.67%-1.95%-9.35%+103.23%+18.31%INVAInnoviva+4.32%+0.12%-11.05%-12.53%-12.53%YMABY-mAbs Therapeutics0.00%0.00%0.00%+99.31%-39.79%Compare Analyst ForecastsCompanyConsensus Rating ScoreConsensus RatingConsensus Price Target% Upside from Current PriceBLUSFBELLUS Health 0.00N/AN/AN/AESPREsperion Therapeutics 2.50Moderate Buy$7.00177.78% UpsideINVAInnoviva 2.71Moderate Buy$37.60116.22% UpsideYMABY-mAbs Therapeutics 1.80Reduce$9.6211.76% UpsideCurrent Analyst Ratings BreakdownLatest ESPR, BLUSF, YMAB, and INVA Analyst RatingsDateCompanyBrokerageActionRatingPrice TargetDetails10/8/2025ESPREsperion TherapeuticsWeiss RatingsSubscribe to MarketBeat All Access for the firm's recommendation accuracy ratingReiterated RatingSell (D-)10/8/2025INVAInnovivaZacks ResearchSubscribe to MarketBeat All Access for the firm's recommendation accuracy ratingUpgradeHold ➝ Strong-Buy10/8/2025INVAInnovivaWeiss RatingsSubscribe to MarketBeat All Access for the firm's recommendation accuracy ratingReiterated RatingHold (C)9/30/2025INVAInnovivaThe Goldman Sachs GroupSubscribe to MarketBeat All Access for the firm's recommendation accuracy ratingInitiated CoverageSell$17.009/30/2025INVAInnovivaThe Goldman Sachs GroupSubscribe to MarketBeat All Access for the firm's recommendation accuracy ratingInitiated CoverageSell$17.009/27/2025ESPREsperion TherapeuticsWeiss RatingsSubscribe to MarketBeat All Access for the firm's recommendation accuracy ratingReiterated RatingSell (D-)9/27/2025INVAInnovivaWeiss RatingsSubscribe to MarketBeat All Access for the firm's recommendation accuracy ratingReiterated RatingHold (C)9/19/2025ESPREsperion TherapeuticsHC WainwrightSubscribe to MarketBeat All Access for the firm's recommendation accuracy ratingReiterated RatingBuy$16.008/11/2025INVAInnovivaHC WainwrightSubscribe to MarketBeat All Access for the firm's recommendation accuracy ratingBoost Price TargetBuy$40.00 ➝ $45.008/11/2025INVAInnovivaOppenheimerSubscribe to MarketBeat All Access for the firm's recommendation accuracy ratingInitiated CoverageOutperform$45.008/6/2025YMABY-mAbs TherapeuticsHC WainwrightSubscribe to MarketBeat All Access for the firm's recommendation accuracy ratingReiterated RatingBuy ➝ Neutral$11.00 ➝ $8.60(Data available from 10/16/2022 forward. View 10+ years of historical ratings with our analyst ratings screener.)Compare Sales & Book ValueCompanyAnnual RevenuePrice/SalesCashflowPrice/CashBook ValuePrice/BookBLUSFBELLUS Health$30K0.00N/AN/A$0.25 per share0.00ESPREsperion Therapeutics$268.13M1.89$0.02 per share112.38($1.97) per share-1.28INVAInnoviva$358.71M3.06$3.57 per share4.87$11.03 per share1.58YMABY-mAbs Therapeutics$87.68M4.46N/AN/A$2.05 per share4.20Compare Profitability & EarningsCompanyNet IncomeEPSTrailing P/E RatioForward P/E RatioP/E GrowthNet MarginsReturn on Equity (ROE)Return on Assets (ROA)Next Earnings DateBLUSFBELLUS Health-$7.01M-$0.10N/AN/AN/A-49,910.34%-48.37%-45.25%N/AESPREsperion Therapeutics-$51.74M-$0.49N/AN/A145.55-35.84%N/A-28.41%11/6/2025 (Estimated)INVAInnoviva$23.39M$0.3156.1011.22N/A10.44%18.67%9.92%11/5/2025 (Estimated)YMABY-mAbs Therapeutics-$29.67M-$0.50N/AN/AN/A-26.03%-24.60%-18.89%11/14/2025 (Estimated)Latest ESPR, BLUSF, YMAB, and INVA EarningsDateQuarterCompanyConsensus EstimateReported EPSBeat/MissGap EPSRevenue EstimateActual RevenueDetails11/6/2025Q3 2025ESPREsperion Therapeutics$0.06N/AN/AN/A$78.33 millionN/A11/5/2025Q3 2025INVAInnoviva$0.46N/AN/AN/A$91.31 millionN/A8/8/2025Q2 2025YMABY-mAbs Therapeutics-$0.27-$0.07+$0.20-$0.07$18.40 million$19.52 million8/6/2025Q2 2025INVAInnoviva$0.57$0.77+$0.20$0.77$87.10 million$100.28 million8/5/2025Q2 2025ESPREsperion Therapeutics-$0.17-$0.02+$0.15-$0.02$62.55 million$82.39 millionCompare DividendsCompanyAnnual PayoutDividend Yield3-Year Dividend GrowthPayout RatioYears of Consecutive GrowthBLUSFBELLUS HealthN/AN/AN/AN/AN/AESPREsperion TherapeuticsN/AN/AN/AN/AN/AINVAInnovivaN/AN/AN/AN/AN/AYMABY-mAbs TherapeuticsN/AN/AN/AN/AN/ACompare DebtCompanyDebt-to-Equity RatioCurrent RatioQuick RatioBLUSFBELLUS HealthN/A13.8713.87ESPREsperion TherapeuticsN/A1.150.76INVAInnoviva0.362.642.44YMABY-mAbs TherapeuticsN/A4.003.58Compare OwnershipInstitutional OwnershipCompanyInstitutional OwnershipBLUSFBELLUS HealthN/AESPREsperion Therapeutics47.39%INVAInnoviva99.12%YMABY-mAbs Therapeutics70.85%Insider OwnershipCompanyInsider OwnershipBLUSFBELLUS Health24.17%ESPREsperion Therapeutics1.70%INVAInnoviva2.25%YMABY-mAbs Therapeutics19.70%Compare Miscellaneous StatsCompanyEmployeesShares OutstandingFree FloatOptionableBLUSFBELLUS Health10159.12 millionN/ANot OptionableESPREsperion Therapeutics200201.62 million198.20 millionOptionableINVAInnoviva10063.02 million61.60 millionOptionableYMABY-mAbs Therapeutics15045.44 million36.49 millionOptionableESPR, BLUSF, YMAB, and INVA HeadlinesRecent News About These CompaniesY-mAbs Therapeutics, Inc. (NASDAQ:YMAB) Given Consensus Recommendation of "Reduce" by AnalystsOctober 12, 2025 | americanbankingnews.comY-mAbs Therapeutics (NASDAQ:YMAB) Upgraded by Wall Street Zen to "Hold" RatingSeptember 20, 2025 | marketbeat.comY-mAbs Therapeutics, Inc. (NASDAQ:YMAB) Receives Consensus Recommendation of "Reduce" from BrokeragesSeptember 17, 2025 | marketbeat.comY-Mabs Therapeutics Completes Merger with Perseus BidCoSeptember 16, 2025 | tipranks.comY-Mabs Therapeutics’ Phase 2 Trial: A Potential Breakthrough for Neuroblastoma TreatmentSeptember 7, 2025 | msn.comY-mAbs Therapeutics, Inc. (YMAB) Now Trades Above Golden Cross: Time to Buy?September 1, 2025 | zacks.comY-MABS THERAPEUTICS INVESTOR ALERT BY THE FORMER ATTORNEY GENERAL OF LOUISIANA: Kahn Swick & Foti, LLC Investigates Adequacy of Price and Process in Proposed Sale of Y-mAbs Therapeutics, Inc. - YMABAugust 19, 2025 | globenewswire.comAcquisition Deal Triggers Weekly Surge for Y-mAbs Therapeutics StockAugust 13, 2025 | insidermonkey.comA Look Ahead: Y-mAbs Therapeutics's Earnings ForecastAugust 9, 2025 | benzinga.comY-mAbs (YMAB) Q2 Revenue Falls 14%August 9, 2025 | aol.comAY-mAbs Therapeutics, Inc. (YMAB) Reports Q2 Loss, Tops Revenue EstimatesAugust 8, 2025 | zacks.comShareholder Alert: The Ademi Firm Investigates Whether Y-mAbs Therapeutics Inc. is Obtaining a Fair Price for its Public ShareholdersAugust 8, 2025 | businesswire.comY-mAbs Reports Second Quarter 2025 Financial Results and Recent Corporate DevelopmentsAugust 8, 2025 | globenewswire.com$HAREHOLDER ALERT: The M&A Class Action Firm Announces An Investigation of Y-mAbs Therapeutics, Inc. (NASDAQ: YMAB)August 7, 2025 | prnewswire.comY-MABS THERAPEUTICS INVESTOR ALERT by the Former Attorney General of Louisiana: Kahn Swick & Foti, LLC Investigates Adequacy of Price and Process in Proposed Sale of Y-mAbs Therapeutics, Inc. - YMABAugust 7, 2025 | businesswire.comY-mAbs Therapeutics, Inc. to Report Q2 2025 Financial Results on August 8, 2025, forgoing Earnings CallAugust 7, 2025 | quiverquant.comQY-mAbs to Announce Second Quarter 2025 Financial and Operating Results on August 8, 2025August 7, 2025 | globenewswire.comHC Wainwright & Co. Downgrades Y-mAbs Therapeutics (YMAB)August 7, 2025 | msn.comSERB bets on rare cancer drug in $412 million deal for Y-mAbsAugust 6, 2025 | thepharmaletter.comTJones Trading Downgrades Y-mAbs Therapeutics (YMAB)August 6, 2025 | msn.comYmAbs Therapeutics (YMAB) Surges 103.3%: Is This an Indication of Further Gains?August 6, 2025 | zacks.comNew MarketBeat Followers Over TimeMedia Sentiment Over TimeESPR, BLUSF, YMAB, and INVA Company DescriptionsBELLUS Health OTCMKTS:BLUSFBELLUS Health, Inc. is a biopharmaceutical development company, which engages in the research and development of products that provide health solutions and address critical unmet medical needs. Its products include BLU-5937, KIACTA, AMO-01, and ALZ-801. The company was founded on June 17, 1993 and is headquartered in Laval, Canada.Esperion Therapeutics NASDAQ:ESPR$2.52 -0.18 (-6.67%) Closing price 10/15/2025 04:00 PM EasternExtended Trading$2.55 +0.03 (+1.19%) As of 06:01 AM Eastern Extended trading is trading that happens on electronic markets outside of regular trading hours. This is a fair market value extended hours price provided by Polygon.io. Learn more.Esperion Therapeutics, Inc., a pharmaceutical company, develops and commercializes medicines for the treatment of patients with elevated low density lipoprotein cholesterol (LDL-C). Its marketed products include NEXLETOL (bempedoic acid) and NEXLIZET (bempedoic acid and ezetimibe) tablets that are oral, once-daily, non-statin medicines for the treatment of primary hyperlipidemia in adults with heterozygous familial hypercholesterolemia or atherosclerotic cardiovascular disease who require additional lowering of LDL-C. The company's products also include NILEMDO, an ATP Citrate Lyase (ACL) inhibitor that lowers LDL-C and cardiovascular risk by reducing cholesterol biosynthesis and up-regulating the LDL receptors; and NUSTENDI, a bempedoic acid and ezetimibe tablet to treat elevated LDL-C. The company has license and collaboration agreements with Daiichi Sankyo Co. Ltd to; Otsuka Pharmaceutical Co., Ltd; and Daiichi Sankyo Europe GmbH. Esperion Therapeutics, Inc. was incorporated in 2008 and is headquartered in Ann Arbor, Michigan.Innoviva NASDAQ:INVA$17.39 +0.72 (+4.32%) Closing price 10/15/2025 04:00 PM EasternExtended Trading$17.48 +0.09 (+0.55%) As of 05:41 AM Eastern Extended trading is trading that happens on electronic markets outside of regular trading hours. This is a fair market value extended hours price provided by Polygon.io. Learn more.Innoviva, Inc. engages in the development and commercialization of pharmaceutical products in the United States and internationally. The company's products include RELVAR/BREO ELLIPTA, a once-daily combination medicine consisting of a LABA, vilanterol (VI), an inhaled corticosteroid (ICS), and fluticasone furoate; ANORO ELLIPTA, a once-daily medicine combining a long-acting muscarinic antagonist (LAMA) and umeclidinium bromide (UMEC) with a LABA, VI; GIAPREZA (angiotensin II), a vasoconstrictor to increase blood pressure in adults with septic or other distributive shock; XERAVA (eravacycline) for the treatment of complicated intra-abdominal infections in adults; and XACDURO, a beta lactamase inhibitor for the treatment of hospital-acquired bacterial pneumonia and ventilator-associated bacterial pneumonia. Its development pipeline includes zoliflodacin, a late-stage product candidate, a potential single oral dose cure for the treatment of uncomplicated gonorrhea. Innoviva, Inc. has a strategic partnership with Sarissa Capital Management LP. It has long-acting beta2 agonist (LABA) collaboration agreement with Glaxo Group Limited to develop and commercialize once-daily products for the treatment of chronic obstructive pulmonary disease and asthma. The company was formerly known as Theravance, Inc. and changed its name to Innoviva, Inc. in January 2016. Innoviva, Inc. was incorporated in 1996 and is headquartered in Burlingame, California.Y-mAbs Therapeutics NASDAQ:YMAB$8.61 0.00 (0.00%) As of 09/16/2025Y-mAbs Therapeutics, Inc., a commercial-stage biopharmaceutical company, focuses on the development and commercialization of antibody based therapeutic products for the treatment of cancer in the United States and internationally. It offers DANYELZA, a monoclonal antibody in combination with granulocyte-macrophage colony-stimulating factor for the treatment of pediatric patients with relapsed or refractory high-risk neuroblastoma in the bone or bone marrow. The company is also developing DANYELZA for the treatment of patients with second-line relapsed osteosarcoma and is in Phase II clinical study; GD2-SADA, which is in Phase I clinical trial for the treatment of GD2 positive solid tumor; and Omburtamab, a murine monoclonal antibody for the treatment of central nervous system/leptomeningeal metastases from neuroblastoma, as well as SADA PRIT technology platform. In addition, it is engages in the developing of CD38-SADA and GD2-GD3 Vaccine. The company has a license agreement with Memorial Sloan Kettering Cancer Center and Massachusetts Institute of Technology to develop and commercialize licensed products. Y-mAbs Therapeutics, Inc. was incorporated in 2015 and is headquartered in New York, New York. More Stock Comparisions from MarketBeat Stock Comparison Ideas (A-K)5GAgricultureAirlineAmerica FirstApparelArtificial IntelligenceAutomotiveBankBiotechBitcoinBlockchainBlue ChipCanadianCannabisCasinoChatGPTChineseCloud StorageCryptocurrencyCybersecurityDefenseDividendDow 30DroneEcommerceElectric VehiclesEnergyEntertainmenteSportsEV ChargingFertilizerFlying CarGoldGroceryGrowthHealthcareHigh DividendHotelStock Comparison Ideas (L-Z)Large CapLeisureLithiumMade In AmericaMagnificent SevenMega CapMemeMetaverseMid CapMiningMusic IndustryNanotechnologyNFTNuclear EnergyOilPharmaceuticalQuantum ComputingRenewable EnergyRestaurantRetailSemiconductorSilverSocial MediaSolarSpaceTechnologyTelecomToyUraniumUtilityVideo GameVirtual RealityWallStreetBets More Stock Ideas from MarketBeat Stock Lists 5G Stocks Biotech Stocks Blue Chip Stocks DOW 30 Stocks FAANG Stocks Gold Stocks Large Cap Stocks Lumber Stocks Marijuana Stocks Micro Cap Stocks Oil Stocks REITs Small Cap Stocks SPACs Travel Stocks Trillion Dollar Stocks Water Stocks Warren Buffett Stocks Low Priced Stocks Penny Stock List Popular Penny Stocks Top Stocks Today Stocks on Sale Stocks Under $0.05 Stocks Under $0.10 Stocks Under $0.25 Stocks Under $0.50 Stocks Under $1 Stocks Under $2 Stocks Under $3 Stocks Under $5 Stocks Under $10 Stocks Under $20 Stocks Under $30 Stocks Under $50 Stocks By Exchange NASDAQ Stocks NYSE Stocks NYSEAMERICAN Stocks NYSEARCA Stocks NYSEMKT Stocks OTCMKTS Stocks TSX Stocks TSXV Stocks LSE Stocks BATS Stocks Latest Stock Ideas Walmart's AI Play: OpenAI Deal Forges a New Path to Profitability 3 Healthcare Companies Insiders Are Buying Tempus AI Hits $100—Are Shares Due for a Pullback? Vertiv Stock Surges on Strategic CFO Hire and AI Momentum NVIDIA Analysts Lift Targets: What It Means for the Stock Price Fastenal Stock Pulls Back in October—Is It Time to Buy FAST? 5 Stocks and ETFs to Weather Volatility as Trade Tensions Rise Why Congress Is Buying Intuitive Surgical Ahead of Earnings Get 30 Days of MarketBeat All Access for Free Sign up for MarketBeat All Access to gain access to MarketBeat's full suite of research tools. Start Your 30-Day Trial MarketBeat All Access Features Best-in-Class Portfolio Monitoring Get personalized stock ideas. Compare portfolio to indices. Check stock news, ratings, SEC filings, and more. Stock Ideas and Recommendations See daily stock ideas from top analysts. Receive short-term trading ideas from MarketBeat. Identify trending stocks on social media. Advanced Stock Screeners and Research Tools Use our seven stock screeners to find suitable stocks. Stay informed with MarketBeat's real-time news. Export data to Excel for personal analysis. Sign in to your free account to enjoy these benefits In-depth profiles and analysis for 20,000 public companies. Real-time analyst ratings, insider transactions, earnings data, and more. Our daily ratings and market update email newsletter. Sign in to your free account to enjoy all that MarketBeat has to offer. Sign In Create Account Your Email Address: Email Address Required Your Password: Password Required Log In or Sign in with Facebook Sign in with Google Forgot your password? Your Email Address: Please enter your email address. Please enter a valid email address Choose a Password: Please enter your password. Your password must be at least 8 characters long and contain at least 1 number, 1 letter, and 1 special character. Create My Account (Free) or Sign in with Facebook Sign in with Google By creating a free account, you agree to our terms of service. This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.
